ACHV

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

CEO: Richard A. Stewart
IPO Date: Oct 12, 1995

Market Data

Volume: 1.1M

Valuation

Market Cap: $563M

Financials

Financial statement snapshot is not available yet.